{"schema_version":"secwatch.filing_event.v1","accession":"0001962918-24-000117","form_type":"8-K/A","ticker":null,"cik":"0001962918","company_name":"ACELYRIN, Inc.","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.455443+00:00","generated_at":"2026-05-30T06:25:35.979298+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ACELYRIN estimates ~$11.5M restructuring charges; cuts 40 jobs, halts izokibep in HS/PsA/AxSpa","bullets":["Workforce reduced by 40 employees (~1/3 headcount); one-time severance costs estimated at $4.3M.","Suspension of izokibep development in HS, PsA, AxSpa; focus shifts to lonigutamab for thyroid eye disease.","Cancellation of manufacturing services yields net charge of ~$7.2M ($42.9M cash expense netted with $35.7M credit voucher).","Q3 2024 restructuring charges preliminarily estimated at $3.6M severance plus full $7.2M manufacturing cancellation charge.","Credit voucher expected to offset future manufacturing costs for lonigutamab through Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001962918-24-000117","json":"https://secwatch.observer/filing/0001962918-24-000117.json","markdown":"https://secwatch.observer/filing/0001962918-24-000117.md","text":"https://secwatch.observer/filing/0001962918-24-000117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962918/000196291824000117/0001962918-24-000117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962918/000196291824000117/slrn-20240810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:25:35.979298+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a2a0488397e543770750a6559eca36cd2360b0c","claim":"ACELYRIN, Inc. announced a restructuring with charges of approximately $7.2 million affecting the Company; cancellation of services under a manufacturing agreement related to suspension of new internal development of izokibep in HS, PsA and AxSpa.","evidence_excerpt":"the Company now estimates that it will incur net restructuring charges of approximately $7.2 million consisting of $42.9 million of cash expense in connection with such cancellation of services netted against a $35.7 million credit voucher","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1962918/000196291824000117/0001962918-24-000117-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $7.2 million"},{"label":"Affected area","value":"the Company; cancellation of services under a manufacturing agreement related to suspension of new internal development of izokibep in HS, PsA and AxSpa"}],"fact_type":"restructuring_charge"},{"claim_id":"eb011dae07fcf226e0b7ccd681bf01391daa3abe","claim":"ACELYRIN, Inc. announced a restructuring with charges of approximately $4.3 million affecting the Company; workforce reduction connected with plan to suspend new internal investment in development of izokibep in HS, PsA and AxSpa (40 people, or approximately 1/3 of the Company’s then-existing headcount).","evidence_excerpt":"the Company now estimates that it will incur restructuring charges totaling approximately $4.3 million consisting of cash-based expenses related to one-time employee severance payments and benefits","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1962918/000196291824000117/0001962918-24-000117-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $4.3 million"},{"label":"Affected area","value":"the Company; workforce reduction connected with plan to suspend new internal investment in development of izokibep in HS, PsA and AxSpa"},{"label":"Headcount","value":"40 people, or approximately 1/3 of the Company’s then-existing headcount"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}